161 related articles for article (PubMed ID: 38160960)
21. Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment.
Shah S; Danda D; Kavadichanda C; Das S; Adarsh MB; Negi VS
Rheumatol Int; 2020 Oct; 40(10):1539-1554. PubMed ID: 32666137
[TBL] [Abstract][Full Text] [Related]
22. The interaction between anti-Ro/SSA and anti-La/SSB autoantibodies and anti-infectious antibodies in a wide spectrum of auto-immune diseases: another angle of the autoimmune mosaic.
Agmon-Levin N; Dagan A; Peri Y; Anaya JM; Selmi C; Tincani A; Bizzaro N; Stojanovich L; Damoiseaux J; Cohen Tervaert JW; Mosca M; Cervera R; Shoenfeld Y
Clin Exp Rheumatol; 2017; 35(6):929-935. PubMed ID: 28770708
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 Infection Triggers Auto-Immune Response in ARDS.
Juanes-Velasco P; Landeira-Viñuela A; García-Vaquero ML; Lecrevisse Q; Herrero R; Ferruelo A; Góngora R; Corrales F; Rivas JL; Lorente JA; Hernández ÁP; Fuentes M
Front Immunol; 2022; 13():732197. PubMed ID: 35154090
[TBL] [Abstract][Full Text] [Related]
24. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
[TBL] [Abstract][Full Text] [Related]
25. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.
van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP
Front Immunol; 2021; 12():781280. PubMed ID: 34987509
[TBL] [Abstract][Full Text] [Related]
26. The onset of
Sacchi MC; Pelazza C; Bertolotti M; Agatea L; De Gaspari P; Tamiazzo S; Ielo D; Stobbione P; Grappiolo M; Bolgeo T; Novel P; Ciriello MM; Maconi A
Autoimmunity; 2023 Dec; 56(1):2229072. PubMed ID: 37381619
[TBL] [Abstract][Full Text] [Related]
27. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
28. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
29. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers.
Scurr MJ; Zelek WM; Lippiatt G; Somerville M; Burnell SEA; Capitani L; Davies K; Lawton H; Tozer T; Rees T; Roberts K; Evans M; Jackson A; Young C; Fairclough L; Tighe P; Wills M; Westwell AD; Morgan BP; Gallimore A; Godkin A
Immunology; 2022 Feb; 165(2):250-259. PubMed ID: 34775604
[TBL] [Abstract][Full Text] [Related]
30. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
Front Immunol; 2021; 12():658519. PubMed ID: 34276652
[TBL] [Abstract][Full Text] [Related]
31. Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.
Egri N; Calderón H; Martinez R; Vazquez M; Gómez-Caverzaschi V; Pascal M; Araújo O; Juan M; González-Navarro EA; Hernández-Rodríguez J
Front Immunol; 2023; 14():1146841. PubMed ID: 37180097
[TBL] [Abstract][Full Text] [Related]
32. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
33. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases.
Vojdani A; Kharrazian D
Clin Immunol; 2020 Aug; 217():108480. PubMed ID: 32461193
[No Abstract] [Full Text] [Related]
34. The Risk of Autoimmunity Development following mRNA COVID-19 Vaccination.
Świerkot J; Madej M; Szmyrka M; Korman L; Sokolik R; Andrasiak I; Morgiel E; Sebastian A
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560659
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2, the autoimmune virus.
Halpert G; Shoenfeld Y
Autoimmun Rev; 2020 Dec; 19(12):102695. PubMed ID: 33130000
[No Abstract] [Full Text] [Related]
36. An autoantigen profile of human A549 lung cells reveals viral and host etiologic molecular attributes of autoimmunity in COVID-19.
Wang JY; Zhang W; Roehrl MW; Roehrl VB; Roehrl MH
J Autoimmun; 2021 Jun; 120():102644. PubMed ID: 33971585
[TBL] [Abstract][Full Text] [Related]
37. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters.
Lu M; Zhang Y; Dravid P; Li A; Zeng C; Kc M; Trivedi S; Sharma H; Chaiwatpongsakorn S; Zani A; Kenney A; Cai C; Ye C; Liang X; Qiu J; Martinez-Sobrido L; Yount JS; Boyaka PN; Liu SL; Peeples ME; Kapoor A; Li J
J Virol; 2021 Sep; 95(20):e0059221. PubMed ID: 34379509
[TBL] [Abstract][Full Text] [Related]
38. The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2).
Beeraka NM; Tulimilli SV; Karnik M; Sadhu SP; Pragada RR; Aliev G; Madhunapantula SV
Biomed Res Int; 2021; 2021():8160860. PubMed ID: 34159203
[TBL] [Abstract][Full Text] [Related]
39. COVID-19 and SLE: Infection and autoimmunity at its best.
Mahroum N; Elsalti A; Ozkan MF; Shoenfeld Y
Lupus; 2023 Dec; 32(14):1591-1597. PubMed ID: 37927085
[TBL] [Abstract][Full Text] [Related]
40. [Importance of autoimmunity induced by SARS-CoV-2 and development of post-vaccination autoimmune diseases].
Montaño-Armendáriz N; Zamudio-Cuevas Y; Fernández-Torres J; Martínez-Flores K; Luján-Juárez IA
Rev Alerg Mex; 2023 Jan; 69(2):78-88. PubMed ID: 36928248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
